Schering-Plough Europe
Rue de Stalle 73
B-1180 Brussels
Belgium
Telephone : +32 2 370 94 16
Fax : +32 2 332 21 85

Date: 11 March 2009

Dr. Eric Abadie
European Medicines Agency
7 Westferry Circus
Canary Wharf
London
E14 4HB
United Kingdom

Subject: Withdrawal of Cylatron (peginterferon alfa-2b), 200, 300 and 600 micrograms/0.5ml, powder and solvent for solution for injection - EMEA/H/C/921

Dear Dr. Abadie,

I would like to inform you that, at this point of time, Schering-Plough Europe has taken the decision to withdraw the application for Marketing Authorisation of Cylatron (peginterferon alfa-2b), 200, 300 and 600 micrograms/0.5ml, powder and solvent for solution for injection, which was intended to be used for the adjuvant treatment of patients with Stage III melanoma as evidenced by microscopic, non-palpable nodal involvement.

This withdrawal is based on the following reason:

- Schering-Plough Europe has taken this decision based on the CHMP's view that the data provided were not sufficient to allow the Committee to conclude a positive benefit-risk balance for Cylatron at this time.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMEA website.

Yours sincerely,
Schering-Plough Europe